卵巢癌患者对口服与静脉复发治疗方案的偏好
该研究采用离散选择实验偏好调查,评估卵巢癌患者对铂耐药、生物标志物阳性疾病可用方案的偏好特征,重点比较口服PARP抑制剂与标准静脉化疗。123名参与者中,2年无进展生存期权重28、费用权重27最为重要;在无进展生存期与费用相同时,49%偏好每月静脉方案,47%偏好口服方案。
要点
- 患者最看重2年无进展生存期与自付费用,给药途径权重较低。
- 接受中度周围神经病变需6个月无进展生存概率从40%升至49%。
- 不存在普遍适用的方案,口服治疗并非所有患者首选。
核心结论
- 卵巢癌患者对复发治疗方案的偏好异质,口服抗癌治疗并非普遍首选,没有一刀切的优选方案。
研究设计与样本
- 离散选择实验偏好调查,对象为卵巢癌女性,共123名参与者,方案概况由7个属性定义。
主要发现
- 参与者中38%经历过复发,25%正在接受化疗,18%正在服用PARP抑制剂。
- 相对重要性权重和为100:2年无进展生存期28、费用27、6个月无进展生存期19、周围神经病变14,记忆问题、恶心与给药方案均≤5。
- 为接受中度周围神经病变,参与者要求6个月无进展生存概率49%(对照40%)或2年概率14%(对照10%)。
- 在无进展生存期与费用相同的三选一中,49%偏好引起轻度记忆问题的每月静脉方案,47%偏好引起中度恶心的口服方案,4%偏好引起轻度记忆问题与轻度周围神经病变的每周静脉方案。
关键数值与推荐
- 属性及水平:给药方案(口服每日、静脉每周、静脉每月);6个月无进展生存概率40%–60%;2年无进展生存概率10%–20%;恶心(无、中度);周围神经病变(无、轻度、中度);记忆问题(无、轻度);自付总费用0至10000美元。
临床怎么用
- 临床决策应结合患者对无进展生存期、费用与不良反应的个人偏好,而非默认口服方案更受青睐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess preferences of women with ovarian cancer regarding features of available anti-cancer regimens for platinum-resistant, biomarker-positive disease, with an emphasis on oral PARP inhibitor and standard intravenous (IV) chemotherapy regimens. METHODS: A discrete-choice-experiment preferences survey was designed, tested, and administered to women with ovarian cancer, with 11 pairs of treatment profiles defined using seven attributes (levels/ranges): regimen (oral daily, IV weekly, IV monthly); probability of progression-free (PFS) at 6 months (40%-60%); probability of PFS at 2 years (10%-20%); nausea (none, moderate); peripheral neuropathy (none, mild, moderate); memory problems (none, mild); and total out-of-pocket cost ($0 to $10,000). RESULTS: Of 123 participants, 38% had experienced recurrence, 25% were currently receiving chemotherapy, and 18% were currently taking a PARP inhibitor. Given attributes and levels, the relative importance weights (sum 100) were: 2-year PFS, 28; cost, 27; 6-month PFS, 19; neuropathy,14; memory problems, nausea, and regimen, all ≤5. To accept moderate neuropathy, participants required a 49% (versus 40%) chance of PFS at 6 months or 14% (versus 10%) chance at 2 years. Given a 3-way choice where PFS and cost were equal, 49% preferred a monthly IV regimen causing mild memory problems, 47% preferred an oral regimen causing moderate nausea, and 4% preferred a weekly IV regimen causing mild memory and mild neuropathy. CONCLUSIONS: These findings challenge the assumption that oral anti-cancer therapies are universally preferred by patients and demonstrate that there is no "one size fits all" regimen that is preferable to women with ovarian cancer when considering recurrence treatment regimens.
引用
- Havrilesky LJ, Scott AL, Davidson BA, et al. The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens. Gynecol Oncol. 2021. PMID: 34053748. doi:10.1016/j.ygyno.2021.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。